Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers

NeuroImage

Volumn 61, Issue 4, 2012, Pages 849-856

  Kågedal, Matts ^a   Cselényi, Zsolt ^a   Nyberg, Svante ^a   Jönsson, Siv ^a   Raboisson, Patrick ^a   Stenkrona, Per ^b   Hooker, Andrew C ^c   Karlsson, Mats O ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

11C AZD9272; MGluR5 receptor; Nonlinear mixed effects modelling; Positron emission tomography; Receptor occupancy

Indexed keywords

AZD 9272; AZD 9272 C 11; CARBON 11; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; RADIOLIGAND; UNCLASSIFIED DRUG;

ANATOMICAL VARIATION; ARTICLE; CEREBELLUM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG PROTEIN BINDING; HUMAN; HUMAN EXPERIMENT; KINETICS; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

BRAIN; CARBON RADIOISOTOPES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KINETICS; LIGANDS; NONLINEAR DYNAMICS; OXADIAZOLES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84861329095     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.02.085     Document Type: Article

References (21)

1. Aarons L. Population approaches/sparse data analysis for human variability in kinetics and dynamics. Environ. Toxicol. Pharmacol. 1996, 2:197-199.
2. Abanades S., van der Aart J., Barletta J., Marzano C., Searle G., Salinas A., Ahmad J., Reiley R., Pampols-Maso S., Zamuner S., Cunningham V., Rabiner E., Laruelle M., Gunn R. Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. J. Cereb. Blood Flow Metab. 2011, 31:944-952.
3. Andersson, J., 2010, Development of PET Radioligands Synthesized from In-Target Produced [11C]Methane. Thesis, (PhD). Karolinska Institutet. (Paper III).
4. NONMEM User's Guides 1989-2006, Icon Development Solutions, Ellicott City, Maryland, USA. S. Beal, L.B. Sheiner, A. Boeckmann (Eds.).
5. Berges A., Zamuner S., Laurijssens B., Gunn R., Cunningham V., Chen C. Using VT (Total Volume of Distribution from PET) in Estimating the PK-Receptor Occupancy Relationship in the Absence of Reference Regions PAGE 17 Abstr 1398. http://www.page-meeting.org/?abstract=1398.
6. Boström E., Hammarlund-Udenaes M., Simonsson U. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology 2008, 108:495-505.
7. Cunningham V.J., Rabiner E.A., Matthews J., Gunn R., Zamuner S., Gee A. Kinetic analysis of neuroreceptor binding using PET. Int. Congr. Ser. 2004, 1265:12-24.
8. Cunningham V.J., Rabiner E.A., Slifstein M., Laruelle M., Gunn R. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J. Cereb. Blood Flow Metab. 2010, 30(1):46-50. 1.
9. 11]raclopride binding to D2-dopamine receptors studied by PET-a comparison to the equilibrium analysis. J. Cereb. Blood Flow Metab. 1989, 9:696-708.
10. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
11. Jonsson E.N., Karlsson M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 1999, 58:51-64.
12. Karlsson M.O., Sheiner L.B. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 1993, 21:735-750.
13. Lassen N.A., Bartenstein P.A., Lammertsma A.A., Prevett tM.C., Turton D.R., Luthra S.K., Osman S., Bloomfield P.M., Jones T., Patsalos P.N., O'Connell M.T., Duncan J.S., Andersen Vanggaard Benzodiazepine receptor quantification in vivo in humans using [llC]flumazenil and PET: application of the steady-state principle. J. Cereb. Blood Flow Metab. 1995, 15:152-165.
14. Liefaard L.C., Ploeger B.A., Molthoff C.F.M., Boellaard R., Lammertsma A.A., Meindert Danhof, Voskuyl R.A. Population pharmacokinetic analysis for simultaneous determination of Bmax and KD in vivo by positron emission tomography. Mol. Imaging Biol. 2005, 7. 411Y421.
15. Lim K.S., Kwon J.S., Jang I.-J., Jeong J.M., Lee J.S., Kim H.W., Kang W.J., Kim J.-R., Cho J.-Y., Kim E., Yoo S.Y., Shin S.-G., Yu K.-S. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin. Pharmacol. Ther. 2007, 81(2).
16. Mawlawi O., Martinez D., Slifstein M., Broft A., Chatterjee R., Hwang D.R., Huang Y., Simpson N., Ngo K., Van Heertum R., Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J. Cereb. Blood Flow Metab. 2001, 21:1034-1057.
17. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol. 1984, 15:217-227.
18. 18F]F-PEB. Nucl. Med. Biol. 2007, 34:1009-1017.
19. Roland P.E., Graufelds C.J., Wåhlin L., Ingelman L., Andersson M., Ledberg A., Pedersen J., Åkerman S., Dabringhaus A., Zilles K. Human Brain Atlas: For high-resolution functional and anatomical mapping. Hum. Brain Mapp. 1994, 1:173-184.
20. 11C-ABP688: assessment of methods. J. Nucl. Med. 2007, 48(7):1207-1215.
21. Zamuner S., Gomeni R., Bye A. Estimate the time varying brain receptor occupancy in PET imaging. Experiments using non-linear fixed and mixed effect modeling approach. Nucl. Med. Biol. 2002, 29:115-123.